Role of pharmacogenetics in public health and clinical health care: a SWOT analysis

被引：27

作者：

Kapoor, Ritika ^{[1
,2
]}

Tan-Koi, Wei Chuen ^{[2
,3
]}

Teo, Yik-Ying ^{[1
,2
,4
,5
,6
]}

机构：

[1] Natl Univ Singapore, Grad Sch Integrat Sci & Engn, Singapore 117456, Singapore

[2] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, MD1,12 Sci Dr 2, Singapore 117549, Singapore

[3] Singapore Minist Hlth, Vigilance & Compliance Branch, Hlth Prod Regulat Grp, Hlth Sci Author, Singapore 138667, Singapore

[4] Natl Univ Singapore, Inst Life Sci, Singapore 117456, Singapore

[5] Agcy Sci Technol & Res, Genome Inst Singapore, Singapore 138672, Singapore

[6] Natl Univ Singapore, Dept Stat & Appl Probabil, Singapore 117546, Singapore

来源：

EUROPEAN JOURNAL OF HUMAN GENETICS | 2016年 / 24卷 / 12期

基金：

欧盟地平线“2020”;

关键词：

COST-EFFECTIVENESS ANALYSIS; TOXIC EPIDERMAL NECROLYSIS; STEVENS-JOHNSON SYNDROME; IMPLEMENTATION CONSORTIUM; HLA-B-ASTERISK-5801; ALLELE; HYPERSENSITIVITY REACTIONS; GENETIC-VARIANTS; WARFARIN; ABACAVIR; ASSOCIATION;

D O I：

10.1038/ejhg.2016.114

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Pharmacogenomics has been lauded as an important innovation in clinical medicine as a result of advances in genomic science. As one of the cornerstones in precision medicine, the vision to determine the right medication in the right dosage for the right treatment with the use of genetic information has not exactly materialised, and few genetic tests have been implemented as the standard of care in health systems worldwide. Here we review the findings from a SWOT analysis to examine the strengths, weaknesses, opportunities and threats around the role of pharmacogenetics in public health and clinical health care, at the micro, meso and macro levels corresponding to the perspectives of the individuals (scientists, patients and physicians), the health-care institutions and the health systems, respectively.

引用

页码：1651 / 1657

页数：7

共 55 条

[1]

Ando Y, 2000, CANCER RES, V60, P6921

[2] Clinical assessment incorporating a personal genome [J].

Ashley, Euan A. ;

Butte, Atul J. ;

Wheeler, Matthew T. ;

Chen, Rong ;

Klein, Teri E. ;

Dewey, Frederick E. ;

Dudley, Joel T. ;

Ormond, Kelly E. ;

Pavlovic, Aleksandra ;

Morgan, Alexander A. ;

Pushkarev, Dmitry ;

Neff, Norma F. ;

Hudgins, Louanne ;

Gong, Li ;

Hodges, Laura M. ;

Berlin, Dorit S. ;

Thorn, Caroline F. ;

Sangkuhl, Katrin ;

Hebert, Joan M. ;

Woon, Mark ;

Sagreiya, Hersh ;

Whaley, Ryan ;

Knowles, Joshua W. ;

Chou, Michael F. ;

Thakuria, Joseph V. ;

Rosenbaum, Abraham M. ;

Zaranek, Alexander Wait ;

Church, George M. ;

Greely, Henry T. ;

Quake, Stephen R. ;

Altman, Russ B. .

LANCET, 2010, 375 (9725) :1525-1535

[3] New Oral Anticoagulants vs. Warfarin Treatment: No Need for Pharmacogenomics? [J].

Baker, W. L. ;

Chamberlin, K. W. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (01) :17-19

[4] Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability [J].

Brown, Jacob T. ;

Bishop, Jeffrey R. .

PHARMACOGENOMICS, 2015, 16 (13) :1513-1520

[5] Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process [J].

Caudle, Kelly E. ;

Klein, Teri E. ;

Hoffman, James M. ;

Mueller, Daniel J. ;

Whirl-Carrillo, Michelle ;

Gong, Li ;

McDonagh, Ellen M. ;

Sangkuhl, Katrin ;

Thorn, Caroline F. ;

Schwab, Matthias ;

Agundez, Jose A. G. ;

Freimuth, Robert R. ;

Huser, Vojtech ;

Lee, Ming Ta Michael ;

Iwuchukwu, Otito F. ;

Crews, Kristine R. ;

Scott, Stuart A. ;

Wadelius, Mia ;

Swen, Jesse J. ;

Tyndale, Rachel F. ;

Stein, C. Michael ;

Roden, Dan ;

Relling, Mary V. ;

Williams, Marc S. ;

Johnson, Samuel G. .

CURRENT DRUG METABOLISM, 2014, 15 (02) :209-217

[6] Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia [J].

Chan, S. L. ;

Suo, C. ;

Lee, S. C. ;

Goh, B. C. ;

Chia, K. S. ;

Teo, Y. Y. .

PHARMACOGENOMICS JOURNAL, 2012, 12 (04) :312-318

[7]

Chan SL, 2012, PHARMACOGENOMICS, V13, P1247, DOI [10.2217/PGS.12.104, 10.2217/pgs.12.104]

[8] A marker for Stevens-Johnson syndrome [J].

Chung, WH ;

Hung, SI ;

Hong, HS ;

Hsih, MS ;

Yang, LC ;

Ho, HC ;

Wu, JY ;

Chen, YT .

NATURE, 2004, 428 (6982) :486-486

[9] Implications of the Human Genome Project for medical science [J].

Collins, FS ;

McKusick, VA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (05) :540-544

[10] A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose [J].

Cooper, Gregory M. ;

Johnson, Julie A. ;

Langaee, Taimour Y. ;

Feng, Hua ;

Stanaway, Ian B. ;

Schwarz, Ute I. ;

Ritchie, Marylyn D. ;

Stein, C. Michael ;

Roden, Dan M. ;

Smith, Joshua D. ;

Veenstra, David L. ;

Rettie, Allan E. ;

Rieder, Mark J. .

BLOOD, 2008, 112 (04) :1022-1027

← 1 2 3 4 5 6 →